Your browser doesn't support javascript.
loading
Bioengineered Ciprofloxacin-Loaded Chitosan Nanoparticles for the Treatment of Bovine Mastitis.
Yadav, Preeti; Yadav, Awadh Bihari; Gaur, Preksha; Mishra, Vartika; Huma, Zul-I; Sharma, Neelesh; Son, Young-Ok.
Affiliation
  • Yadav P; Centre of Biotechnology, University of Allahabad, Pryagraj 211002, India.
  • Yadav AB; Centre of Biotechnology, University of Allahabad, Pryagraj 211002, India.
  • Gaur P; Centre of Biotechnology, University of Allahabad, Pryagraj 211002, India.
  • Mishra V; Centre of Biotechnology, University of Allahabad, Pryagraj 211002, India.
  • Huma ZI; Division of Veterinary Medicine, Faculty of Veterinary Sciences and Animal Husbandry, Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu, R.S. Pura, Jammu 181102, India.
  • Sharma N; Division of Veterinary Medicine, Faculty of Veterinary Sciences and Animal Husbandry, Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu, R.S. Pura, Jammu 181102, India.
  • Son YO; Department of Animal Biotechnology, Faculty of Biotechnology, College of Applied Life Sciences, Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 690756, Republic of Korea.
Biomedicines ; 10(12)2022 Dec 19.
Article in En | MEDLINE | ID: mdl-36552038
Mastitis is the most devastating economic disease in dairy cattle. Mastitis in dairy cattle frequently occurs during the dry period or during early lactation. Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus)are the main causative agents of mastitis in India. S. aureus can form microabscesses in the udder and develop a subclinical form of mastitis. This bacterial property hinders an effective cure during the lactation period. Antimicrobials used for treatments have a short half-life at the site of action because of frequent milking; thereforethey are unable to maintain the desired drug concentration for effective clearance of bacteria. We demonstrated the potential of ciprofloxacin-encapsulated nanocarriersthat can improve the availability of drugs and provide an effective means for mastitis treatment. These drug-loaded nanoparticles show low toxicity and slow clearance from the site of action. Antimicrobial activity against clinical strains of E. coli and S. aureus showed that the zone of inhibition depended on the dose (0.5 mg to 2 mg/mL nanoparticle solution from 11.6 to 14.5 mm and 15 to 18 mm). These nanoparticles showed good antimicrobial activity in broth culture and agar diffusion assay against bacteria.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomedicines Year: 2022 Document type: Article Affiliation country: India Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomedicines Year: 2022 Document type: Article Affiliation country: India Country of publication: Switzerland